Body Vision Medical, a Ramat Ha Sharon, Israel-based commercial-stage medical device company specializing in lung cancer diagnostics and treatment through real-time software technologies, closed a $20m Series C funding.
Backers were not disclosed.
The company intends to use the funds to streamline commercialization and manufacturing activities for its LungVisionTM 2.0 Platform.
Founded in 2014 by Dorian Averbuch, CEO, Body Vision Medical is a software and medical device company specializing in augmented real-time fusion imaging, artificial intelligence and intra-body navigation.
Its LungVisionTM 2.0 Platform, which received FDA clearance in May 2019, features AI Tomography, fused imaging, cloud-based machine learning and multi-modality image registration.